Keytruda (pembrolizumab) carries a list price that puts it among the most expensive drugs in the United States, with a full course of treatment running well into six figures for many cancer types. But the number on the price tag and what you hand over are rarely the same thing. Your actual out-of-pocket cost depends on the type of insurance you have, where you receive your infusions, and whether you qualify for financial assistance programs. For a Medicare beneficiary on a standard early breast cancer regimen, coinsurance alone can exceed $40,000, while a commercially insured patient might pay a fraction of that or, in some cases, nothing at all.
What Medicare Pays and What You Owe
Because Keytruda is given by infusion in a clinic or hospital, it falls under Medicare Part B rather than Part D. That distinction matters a lot for your wallet. Part B generally covers 80 percent of the approved amount, leaving you responsible for the remaining 20 percent coinsurance with no annual cap on out-of-pocket spending. For an expensive biologic, that 20 percent adds up fast.
A recent analysis of Medicare Part B payment rates for early breast cancer illustrates the scale. For a 70-kilogram patient receiving a pembrolizumab-based regimen for triple-negative breast cancer, Medicare paid roughly $212,000, and the patient’s coinsurance liability came to about $42,400. Pembrolizumab itself accounted for more than 90 percent of that total cost.1Clinical Cancer Research. Abstract PS4-11-01: Medicare Part B Drug Cost Burden of Pembrolizumab Based Triple Negative and Dual HER2 Triple Positive Regimens for Early Breast Cancer at 2025 Q3 Payment Rates For context, that coinsurance figure alone is close to the median annual household income in some parts of the country.
Patients on Original Medicare who also carry a Medigap supplemental plan can have most or all of that coinsurance covered, depending on the plan. But not everyone has Medigap, and Medicare Advantage plans handle cost-sharing differently, sometimes with their own specialty drug tiers, prior authorization requirements, and annual out-of-pocket maximums. Research has found that Keytruda’s high cost-sharing is associated with Medicare Advantage beneficiaries switching to Original Medicare with Medigap coverage in states where guaranteed-issue protections make that switch easier.2Health Affairs Scholar. Medigap-guaranteed issue associated with Medicare Advantage disenrollment for beneficiaries administered a part B drug In states with strong guaranteed-issue laws, the probability of disenrolling from Medicare Advantage after starting Keytruda was nearly nine percentage points higher than in states without such protections. That is a real signal that patients are making insurance decisions specifically because of this drug’s cost.
How Insurance Type Changes Patient Responsibility
The gap between what different patients pay for the same drug is enormous. A study of immunotherapy claims found that average patient responsibility for off-label immunotherapy agents varied dramatically by payer type: commercially insured patients averaged about $657 per patient, Medicare Advantage patients about $1,248, and Original Medicare beneficiaries roughly $7,436.3Journal of Clinical Oncology. Off-label immunotherapy prescription: Financial implications for payers and patients Medicaid patients paid nothing. These numbers reflect the structural differences in how each insurance type handles cost-sharing, not any difference in the drug itself.
Commercial insurance plans typically have annual out-of-pocket maximums, which means your exposure is capped even when receiving a drug this expensive. Once you hit that cap, the plan covers the rest. Original Medicare, by contrast, has no such ceiling on Part B cost-sharing. That single design choice explains much of the disparity. If you are on Original Medicare without supplemental coverage and your oncologist recommends Keytruda, you are staring at potentially tens of thousands of dollars in coinsurance with no automatic stopping point.
Where You Get Infused Matters More Than You Would Expect
Keytruda’s cost to you is also shaped by something most patients never think about: whether you receive your infusion at a hospital outpatient department or a community oncology practice. Hospitals and clinics buy Keytruda at different prices and bill insurers at different rates, and those differences are substantial.
A study examining Keytruda’s profitability across care settings found that hospitals eligible for the federal 340B drug pricing program marked up the drug by an average of 173 percent over what they paid for it. Hospitals not eligible for 340B discounts marked it up about 78 percent. Community physician practices, by contrast, marked it up roughly 16 percent.4PubMed. Profitability Of Infused Biologics For Hospitals And Physician Practices: Case Study Of Keytruda In dollar terms, each Keytruda patient generated about $102,680 in annual revenue for a 340B-eligible hospital, $67,825 for a non-eligible hospital, and just $3,094 for a community practice.
The 340B program was created to help safety-net hospitals serve low-income patients by allowing them to buy drugs at steep discounts. But the savings from those discounts do not always flow to patients. The hospital buys the drug cheaply, bills the insurer at the standard reimbursement rate, and keeps the spread. For patients whose cost-sharing is calculated as a percentage of the billed amount, being treated at a hospital with a high markup can translate into a larger bill. If you have the option to receive Keytruda at a community oncology clinic rather than a hospital outpatient department, it is worth asking whether the cost-sharing differs.
The Gap Between List Price and Net Price
Keytruda’s list price is the number that gets headlines, but it is not what most payers actually remit to Merck after rebates and discounts. An analysis of the top-selling brand-name drugs found that Keytruda had one of the smallest discounts from its list price in 2015, with an estimated discount of about 23 percent.5JAMA Health Forum. Estimates of Medicaid and Non-Medicaid Net Prices of Top-Selling Brand-name Drugs Incorporating Best Price Rebates, 2015 to 2019 That means insurers and pharmacy benefit managers were paying roughly 77 cents on the dollar. Some other drugs in the same analysis had discounts as steep as 83 percent.
A small discount relative to other blockbuster drugs means there is less room between the sticker price and the actual transaction price. For patients, that translates into higher cost-sharing, because their coinsurance or copay is often calculated from the pre-rebate price. The rebate goes back to the insurer or pharmacy benefit manager, not to you at the pharmacy window or the infusion chair. So even though the system is paying less than list price, your share is pegged to the higher number.
Financial Assistance Programs and Their Limits
Merck operates a patient assistance program for Keytruda, and independent foundations also help cover copays and coinsurance. These programs exist because the drug’s cost-sharing would otherwise be prohibitive for many patients. One study of cancer care safety-net options found that eight foundations provided about $240,000 in patient insurance copayments, while nine manufacturers supplied more than 2,200 free drug doses valued at roughly $3.4 million.6Journal of Managed Care & Specialty Pharmacy. The Financial Effect of Medicare Coverage Design and Safety Net Options for Cancer Care Those numbers sound large, but they represent a fraction of total spending on these drugs, and not every patient who needs help qualifies or knows to apply.
For commercially insured patients, manufacturer copay cards can reduce out-of-pocket costs to nearly zero. But there is a catch that has grown more common in recent years: copay accumulator and copay maximizer programs. Under a traditional plan, a manufacturer’s copay card payment counts toward your annual deductible and out-of-pocket maximum. Once you hit that maximum, you are done paying for the year. Copay accumulators change the rules so that the manufacturer’s payment does not count toward your maximum. When the copay card runs out mid-year, you suddenly owe the full cost-sharing amount.
Research on copay maximizer programs specifically found that when a patient’s baseline liability for the drug was around $4,000, these programs were associated with a 51 percent increase in patient liabilities for other health care services.7PubMed Central. Impact of copay maximizers on total patient liability among patients using specialty medicines The programs essentially restructured cost-sharing so that the manufacturer’s money went entirely to the drug, leaving the patient exposed to higher costs for everything else.
Some states have fought back. States that banned copay accumulator adjustment programs saw patient liabilities drop by 41 to 63 percent after the first two months compared with states that did not, with monthly savings ranging from $128 to $520. Patients in ban states were also 14 percent more likely to stay adherent to their treatment and 13 percent less likely to stop treatment entirely.8PubMed Central. Patient liability, treatment adherence, and treatment persistence associated with state bans of copay accumulator adjustment programs Whether your state has such a ban can meaningfully change what Keytruda costs you, so it is worth checking before treatment starts.
Financial Hardship Goes Beyond the Drug Bill
The out-of-pocket cost of Keytruda is only part of the financial picture. Treatment usually means regular infusion visits, imaging, blood work, managing side effects, and sometimes missing work. Researchers have a term for the cumulative economic strain: financial toxicity. And the data suggest it is widespread among immunotherapy patients.
A study of patients with metastatic non-small-cell lung cancer receiving immunotherapy or chemoimmunotherapy found that a third experienced material financial hardship, nearly two-thirds reported psychological financial distress, and more than half changed their spending behavior because of costs. Over half reported hardship in at least two of those categories simultaneously.9PubMed Central. Unmet Care Needs and Financial Hardship in Patients With Metastatic Non-Small-Cell Lung Cancer on Immunotherapy or Chemoimmunotherapy in Clinical Practice That means even among patients who technically have insurance coverage, the financial weight of treatment is changing how they live.
Among Medicare beneficiaries specifically, high-cost immunotherapy was linked to a 7.2 percentage-point increase in the inability to afford medical care. The effects were worse for blood cancer survivors, who experienced a nearly 24 percentage-point increase in inability to afford medical care and a 43 percentage-point increase in taking fewer medications than prescribed.10PubMed Central. Financial burden of high-cost immunotherapy among cancer survivors in Medicare When people start skipping medications because they cannot afford them, the cost of the drug is no longer an abstract billing question. It is a clinical problem.
Side Effects Carry Their Own Price Tag
Keytruda works by releasing the brakes on the immune system, which means it can sometimes trigger the immune system to attack healthy tissue. These immune-related adverse events can range from mild skin rashes to serious inflammation of the lungs, liver, or endocrine glands. Managing the more serious reactions requires additional treatment, hospitalizations, and specialist visits, all of which add cost.
A modeling study estimated the cost of managing severe immune-related adverse events in metastatic melanoma patients. For anti-PD-1 therapies like Keytruda, the estimated management cost per patient was roughly €49, which is relatively modest compared with combination immunotherapy regimens that ran closer to €277 per patient.11PubMed. Cost Estimate of Immune-Related Adverse Reactions Associated with Innovative Treatments of Metastatic Melanoma Those figures reflect the direct medical costs of managing side effects, not the patient’s share, and they will vary by country and care setting. Still, they confirm that the drug’s sticker price is not the full cost of treatment. If you develop a serious immune-related reaction, your total medical bills for that period can spike considerably.
Getting Insurance to Approve Treatment
Before cost-sharing even enters the picture, you need your insurer to agree to pay. For Keytruda, that usually means prior authorization, a process where the insurance company reviews whether the drug is medically necessary for your specific diagnosis. Keytruda has FDA approval for more than 30 cancer types and treatment settings, which helps, but off-label use and certain indications can trigger denials.
One hospital system that implemented a proactive medical necessity review program for outpatient drugs, including expensive biologics, found that after evaluating 526 drug orders over a year and completing 146 interventions, more than 99 percent of the affected claims were ultimately paid. Only three cases resulted in revenue loss.12American Journal of Health-System Pharmacy. A proactive medical necessity review program reduces revenue loss associated with outpatient medical benefit drugs The takeaway for patients is that denials can often be overturned, but someone has to do the work of documenting medical necessity before or immediately after the claim is submitted. If your oncology team has a financial navigator or prior authorization specialist, lean on them. If not, ask your insurer exactly what documentation they need and push for an appeal if you get denied.
The Inflation Reduction Act and What Might Change
The Inflation Reduction Act of 2022 gave the federal government the authority to negotiate prices directly with manufacturers for certain high-spending drugs. The program requires the Department of Health and Human Services to negotiate on select drugs among the 50 with the highest spending under Medicare Part D and the 50 highest under Medicare Part B. Negotiated Part B prices take effect starting in 2028.13USC Schaeffer Center. Policy Recommendations for the Inflation Reduction Act’s Drug Pricing Provisions
However, the law’s eligibility criteria create a significant timing issue for biologics like Keytruda. Drugs are only eligible for negotiation 13 years after FDA approval for biologics, or nine years for small-molecule drugs. Keytruda received its first FDA approval in 2014, which means it would not become eligible for Medicare price negotiation under the current rules until 2027 at the earliest, with any negotiated price potentially not taking effect until 2028 or later. Certain exclusions also apply: drugs with generic or biosimilar competition, orphan drugs, and small biotech drugs are excluded from the program.
Whether Keytruda ends up on the negotiation list and what the negotiated price might look like remain open questions. But for current patients, the practical reality is that relief from this mechanism is still years away. In the meantime, the levers you can actually pull are the ones already described: supplemental insurance, financial assistance programs, checking whether your state bans copay accumulators, and choosing a treatment site where cost-sharing may be lower.
Practical Steps to Reduce What You Pay
If you or someone you care about is about to start Keytruda, a few concrete actions can make a real difference in the final bill:
- Ask about treatment site: If your oncologist has privileges at both a hospital outpatient center and a community practice, ask whether receiving infusions at the community site would reduce your cost-sharing. The markup differences between settings are large enough to change your bill by thousands of dollars per year.
- Apply for assistance early: Merck’s patient assistance program and independent foundations like the Patient Advocate Foundation and CancerCare have funds specifically for immunotherapy patients. Applications take time, and some funds run out, so apply before your first infusion if possible.
- Understand your copay card: If you are commercially insured and receive a manufacturer copay card, ask your insurer whether they use a copay accumulator or maximizer program. If they do, plan for the possibility that you will owe significant cost-sharing once the card’s value is exhausted.
- Check your state’s laws: A growing number of states have banned copay accumulator programs. If you live in one, your manufacturer copay assistance should count toward your out-of-pocket maximum, giving you year-round protection.
- Review Medicare options carefully: If you are on Medicare Advantage and facing high coinsurance, evaluate whether switching to Original Medicare with a Medigap supplement during open enrollment would lower your total costs. This calculation depends on your state’s guaranteed-issue rules and the premiums involved, but for a drug this expensive, the math often favors Medigap.
- Request a financial navigator: Many cancer centers employ financial counselors or navigators who specialize in helping patients manage treatment costs. They know which programs you qualify for and can handle prior authorization paperwork. If your treatment center has one, use them.
The gap between Keytruda’s headline price and what any individual patient pays is wide, shaped by insurance type, geography, care setting, and whether you know to ask for help. The system is not designed to make this easy to navigate, but the variation also means there is almost always room to lower what you owe if you know where to look.